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INTRODUCTION
Hemolytic disease of the newborn was first described in the medical literature 1609, when it was diagnosed in one French housewife. In 1932 Diamond and colleagues described the mutual relationship of fetal hydrops, jaundice, anemia and erythoblastosis, which was later called fetal erytroblastosis. In 1940s Landsteiner and Weiner also made discovery of the blood Rh factor within the blood type and in 1953 Chown confirmed that the pathogenesis of Rh alloimmunization is the result of the passage of Rh-positive red blood cells of the fetus, after or during transplacental hemorrhage which are antigens in the mother's circulation (1, 2) .
According to the U.S. Center for Disease Control and Prevention, during the 1996 in the United States were recorded 21 deaths of children which can be attributed to hemolytic disease (erytroblastosis fetalis) and jaundice. Determination of blood type in ABO Rh D negative pregnant women allows reasonable precautions which limit the risk to fetus. Erythoblastosis is a very serious medical condition for about 4000 babies a year. In 15% of cases of babies die before birth. Those who survive may suffer from jaundice, which leads to the deaf-muteness, speech disturbances, cerebral palsy and mental retardation (1, 2) .
Rh antigens are lipoprotein molecules, which are sparsely located at the erythrocyte surface. About 50 of them can be identified, which indicates the specific complexity of the Rh antigen. D antigen is the most immunogenic and therefore the most important antigen. It causes the formation of antibodies 50 times more often than the C and E antigens. Rh D negative people do not have the D antigen in the Caucasian population, 85% of people are Rh positive and 15% Rh negative (2, 4). The frequency of Rh negative women than is more common for Caucasian women (15%) than African American (5%) and is less common in Asian women (2, 3, 7, 8, 9) .
Antibodies from Rh system are almost always immune, predominantly in the IgG class, passing due to its size through the umbilical cord and cause hemolytic disease of the newborn (HDN). Under HDN in the strict sense is considered disease whose basis is accelerated immune destruction of fetal/child erythrocytes that are bound to IgG antibodies of maternal origin. Th ese antibodies are directed against antigens of father's origin, which are present in the fetal/children's erythrocytes and that the mother's immune system recognizes them as foreign antigens. Th is happens if the fetal red blood cells enter mother's circulation (3, 5) . Sensitization occurs during childbirth when the mother's bloodstream penetrates certain amount of Rh positive child erythrocytes. Erythrocytes, as foreign substance to the mother, encouraged her body to begin to produce Rh antibodies. Th erefore, the second and other pregnancy can have complications related to maternal Rh antibodies to Rh positive fetal red blood cells (1, 2, 3, 5, 6, 7, 8, 9) .
Th eir appearance in the circulation is also possible aft er amniocentesis, spontaneous or induced abortion, cardiocentesis, chorionic villus sampling, ruptured ectopic pregnancy and a blunt trauma to the abdomen (5).
In the case of specifi c antigen immune stimuli that person does not have, can occur the creation of IgG anti-A and anti-B antibodies, which can pass the placenta and cause destruction of fetal red blood cells (1, 2, 3, 4, 5).
GOAL
Th e goal is that in the period from January 1 st 2011 to October 23 rd 2013 determine the frequency of ABO and Rh D incompatibilities in our sample of pregnant women/mothers, and to underscore the importance of regular check of ABO Rh D negative pregnant women and application specifi c Rh D protection.
MATERIAL AND METHODS
Testing was performed on selected samples that comprised pregnant women at diff erent fertile and gestational age. In the General Hospital "Prim. Dr. Abdulah Nakas" in Sarajevo by retrospective study which covered a period of three years from Most of immune antibodies appear in mothers with O Rh D: negative blood type. Th e emergence of immune antibodies in the Rh D negative mothers was 1%, the appearance of ABO incompatibilities amounted to 2.3% of our sample.
DISCUSSION
In the sample examined ABO Rh D negative mothers we found that in a three years period of in 1% of cases occurred Rh D immune antibodies. It is important to emphasize that they most oft en occur in mothers with O Rh D: negative blood type, where Rh D immunization is higher. ABO immunization is more common in alloimmunization with antigen A pregnant O Rh D negative blood type. In our sample of Rh D incompatibilities occurring mostly in O blood type mothers. All pregnant women in our sample did not have test to immune antibodies in the serum during follow up in our hospital pregnancy is managed in other institutions while they fi rst come for delivery.
Th e risk of Rh D alloimmunization aft er fi rst birth is 16 % if the fetus is ABO compatible with the mother, 2 % if it is not compatible and 2 % aft er termination of pregnancy. Rh sensitization refers to the level fetomaternal hemorrhage (3 % < 0.1 ml and 22 % > 0.1 ml) (1, 2, 8, 9) . When a mother produces antibodies against the blood of unborn fetus, pregnancy is carefully monitored. If the fetus is in danger in pregnancy of at least 32-34 weeks, delivery is induced. Below 32 weeks of pregnancy to the fetus is given a blood transfusion while still in the uterus. Th ere are two techniques that are used to perform a blood transfusion before the birth. Firstly needle is inserted through the mother's abdomen and uterus to fetus abdomen. Erythrocytes are injected/inserted into the fetus's abdominal cavity which is further absorbed into the bloodstream. In early pregnancy, or if the bilirubin level is extremely high cardiocentesis is performed. Th is procedure is based on placing a thin needle through the mother's abdomen, guided by ultrasound in the umbilical vein and erythrocytes are injected directly into the fetus's bloodstream (2). Aft er birth is estimated the severity of symptoms shown by the newborn. One or more transfusions may be necessary to prevent anemia, hyperbilirubinemia and hemorrhage. Hyperbilirubinemia is also treated with phototherapy (2, 8, 9) .
Before the introduction of immunoprophylaxis the immunization incidence of Rh D negative multiparas with Rh D positive child to Rh D antigen was approximately 18%. Introducing postnatal Rh D immunization of pregnant women (Rhogam) reduced the incidence of immunization to less than 1%. Th e introduction of combined antenatal (at 28 th week of gestation) and postnatal Rh D immunization of pregnant women the incidence of immunization is reduced to less than 0.1% (5,7). With or without antenatal immunoprophylaxis all Rh D negative pregnant women who gave birth to Rh D positive fetus and not immunized with the D antigen, should receive 100-300 mg (500-1500 IU) Rh Ig IM within the fi rst 72 hours aft er delivery. Rh Ig dose should be adjusted to the size of fetus-maternal hemorrhage. It is estimated by Kleihauer-Betke gel agglutination or other testing of maternal blood sample taken up to 1 hour aft er birth. Signifi cant fetal-maternal hemorrhage requiring Rh D immunoprophylaxis in doses higher than the standard usually occurs during the traumatic delivery (including caesarean section), the manual removal of the placenta, intrauterine fetal death, stillborn, abdominal trauma in the third trimester of pregnancy, simultaneous delivery of two or more children and/or unexplained fetal hydrops. Rh Ig should receive Rh D negative women not immunized aft er each "event" that could lead to the entry of fetal blood in their circulation (amniocentesis, ectopic pregnancy, spontaneous abortion aft er 12 weeks, induced abortion, cardiocentesis, bleeding before birth, fetal death...) (5, 7, 8, 9) . Prevention of HBN is successful when hyperimmune Rh D gammaglobulin is used in 28/29 and 32/34 week of pregnancy (6, 7) .
In our case, we do not diff ers according to the emergence of immune antibodies from other mentioned in the literature, however, we assume that some pregnant women cannot, because of their social status, buy Rh D immunoprophylaxis which costs 
In the sample examined ABO Rh D negative mothers we found that in a three years period of in 1% of cases occurred Rh D immune antibodies. It is important to emphasize that they most often occur in mothers with O Rh D: negative blood type, where Rh D immunization is higher. ABO immunization is more common in alloimmunization with antigen A pregnant O Rh D negative blood type. In our sample of Rh D incompatibilities occurring mostly in O blood type mothers. All pregnant women in our sample did not have test to immune antibodies in the serum during follow up in our hospital pregnancy is managed in other institutions while they first come for delivery. In case of ABO incompatibilities in 15% of pregnancies mother with O blood type give birth to a child with A or B blood type antigen, the incidence of ABO HDN is rare and occurs 1/150 pregnancies. ABO HDN can occur in any pregnancy, including the first. Its symptoms are usually mild and usually manifest in the neonatal period. Usually within the first 36 hours after birth in the newborn is observed increase of indirect bilirubin levels and mild anemia. Newborns with ABO HDN are usually treated with phototherapy. Less than 2% of newborns needs blood transfusion (5, 7, 8 ).
CONCLUSION
The emergence of Rh D immune antibodies in the serum of our sample is 1% and ABO incompatibilities 2.3% during the period from January 1 st 2011 -October 23 rd 2013. In order to reduce the occurrence of alloimmunization of the mother to erythrocyte antigens of the newborn that can lead to major complications in subsequent pregnancies of Rh D: negative mothers and HDN constant monitoring in order to prevent them is necessary. Prevention is essential because once immunized mother will remain immunized for life. Because the social status in Bosnia and Herzegovina is low, the possibility of increased sensitization of pregnant women could be on the rise. Therefore, one recommendation would be to make the preparation of anti-IgG. (Rhogam) free of charge. Immunization of mothers on erythrocyte antigens is rare but the disease HDN erythoblastosis is a very serious medical condition and the in socially vulnerable population it could have a tendency to increase due to the inability to purchase anti-IgG products.
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